Tech Titans and Pharma Gains: Palo Alto, PayPal, Eli Lilly Shine

1. Palo Alto Networks (Nasdaq: PANW)
Palo Alto Networks surged by 7.18%. Palo Alto Networks reported an 18.19% year-over-year revenue increase to $5.838 billion and strong Q4 FY2024. Scotiabank, Oppenheimer, and JP Morgan maintain ratings of sector outperform and overweight with updated price targets of $400, $410, and $387, respectively.

2. Paypal Holdings (Nasdaq: PYPL)
Paypal Holdings gained solidly by 3.54%. PayPal Holdings reported $15.584 billion in revenue and $2.016 billion net profit for H1 2024. JP Morgan, Barclays, and Baird maintained "Overweight" ratings with price targets of $80 and $85. Daiwa Capital upgraded to "Outperform," and Argus Research upgraded to "Buy."

3. Eli Lilly Andmpany (NYSE: LLY)
Eli Lilly Andmpany gained solidly by 3.08%. Eli Lilly experienced a notable trading day on August 20 with five insider transactions disclosed. Their GLP-1 drug significantly reduces type 2 diabetes risk in prediabetic, overweight adults. Additionally, Eli Lilly expanded its Emgality commercialization agreement with Organon to 11 new markets.